MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. Co.'s primary product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Co. collaborates with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI. We show 23 historical shares outstanding datapoints in our coverage of MNKD's shares outstanding history.
Understanding the changing numbers of MNKD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MNKD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MNKD by allowing them to research MNKD shares outstanding history
as well as any other stock in our coverage universe. |
Free MNKD Email Alerts:
Video: Shares Outstanding Importance
